Working Groups

Discussions on how to effectively facilitate and maintain sustainable Working Groups are still underway. If you are interested in joining, creating or running a Working Group, please reach out to info@atmpsweden.com

Below are previously initiated Working Groups:

• Patient access – Viktor Dansk/Åse Rosenqvist, Björn Skölving, Fredrik Jerhammar, Astrid Wirén, Kinga Täckström, Peter Carlqvist, Peter Hertzman. Suggested additions: Mikael Svensson, Peter Lindgren and Linus Jönsson.
  • HE models suitable for ATMP modalities
  • Payment models suitable for ATMP HE assessments
  • Integrating education around ATMPs into existing training programs
  • Feeding information back to early stage developers
• Women in advanced therapies – Jenny Stjernberg, Jennifer Rosendahl, Lucienne Vonk, Ila Jasra and Ewa Ellis. Suggested additions: Evren Alici, Darcy Wagner, Angelica Loskog and Kinga Täckström
  • Recognising the benefits of diversity and supporting its implementation
• Enabling academic ATMP developments – Henrik Moller Thomsen
  • major gaps in the bench to bedside pipeline eg. researchers, developers/PD, manufacturing and treating physicians.
  • working to solve these gaps through information, education and “match making”
• Chemistry Manufacturing and Control (CMC) – Lilian Walther Jallow, Erik Steffensen, Anna Pasetto, Zhong Yu, Ila Jasra, Anna Renglin Lindh.
• Nordic collaboration – Jes Lauritzen/Chemometec, Seppo Yla-Herttuala, Erika Gurzeler-Tiihonen – Finland, Lucy David, Alice Giraud – Cytiva, Luisa Lundin, Eva-Karin Gidlund – NorthX Biologics, Bo Wiinberg, Lise Gehl Svendsen – Novo Nordisk Foundation Cellerator, Jim Lund, Fredrik Wessberg – CCRM Nordic, Jesper Hedberg – Testa Center, Charlotte Schönbeck – Getinge, Malin Kele – Biolamina, John Coleman – YSDS, Xx – Biotage, Mathias Krieger – FinVector
• ATMP-KIDS – Annakarin Svenningson, Kerstin Sollerbrant, Oskar Ahlberg
• Gene editing – suggested additions: Per Rexen, Luke Pase, Ibrahim Domian, Simona Graziano, Maria Sobol
• Patient organisation engagement – Dag Larsson, Ahmed Elserafy, Suggested additions: Fredrik Östman and Mats Jerkeman.
  • Patients contributing to product development and clinical trials design
  • Access to information on therapeutic options and clinical trials
  • educating on what ATMPs are with real world examples of medicines developed in Sweden/in trial/market approved
  • bring in as many patient foundations as possible to discuss setting up a platform where patients/public can find information about ATMP clinical trials and ask questions about unproven therapies or stem cell tourism. Examples…
    • My Cancer Navigator: information service for people with cancer | Anticancer Fund
    • Clinical Trials in the European Union – EMA (europa.eu)
    • CIRM – California’s Stem Cell Agency
    • Welcome to your home for Gene and Cell Therapy Information | EuroGCT
  • establish a ’buddy’ system where we have an ATMP ambassador for each patient foundation who provides a yearly update on what is happening in the space
    • couple to companies developing in the space – medicine design, valuable clinical outcomes
  • establish a patient registry where individuals can submit their interest to be consulted about medicine development relevant to them. This would be a bit of a match making service to ensure that the volume of patient perspectives needed are engaged